Trial Profile

Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Basal cell cancer; Biliary cancer; Carcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Glioma; Head and neck cancer; Hereditary nonpolyposis colorectal cancer; Ovarian cancer; Pancreatic cancer; Penile cancer; Renal cell carcinoma; Skin cancer; Squamous cell cancer; Urogenital cancer
Focus Therapeutic Use
Acronyms AcSe-nivolumab; UNICANCER AcSe NIVOLUMAB

26 Feb 2024 Status changed from active, no longer recruiting to completed.
24 Oct 2023 Results (n=50) presented at the 48th European Society for Medical Oncology Congress
01 Aug 2023 Results assessing safety and efficacy of nivolumab in several cohorts of rare, advanced cancer published in the Cancer Immunology Immunotherapy

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com